drugset / Trial / NCT05460364

A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects

NCT05460364 ↗

Phase 1 Completed 36 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and compare the safety and tolerability after repeated separate or combined administrations of BR1018-1 and BR1018-2 in healthy adults.

Timeline

Start
2022-08-04
Primary completion
2022-10-17
Completion
2022-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject BR1018-1 Unknown — —
Subject BR1018-2 Unknown — —